NO940524L - - Google Patents

Info

Publication number
NO940524L
NO940524L NO940524A NO940524A NO940524L NO 940524 L NO940524 L NO 940524L NO 940524 A NO940524 A NO 940524A NO 940524 A NO940524 A NO 940524A NO 940524 L NO940524 L NO 940524L
Authority
NO
Norway
Prior art keywords
condensed
bases
inorganic
compounds
processes
Prior art date
Application number
NO940524A
Other languages
English (en)
Other versions
NO940524D0 (no
Original Assignee
Thomae Gmbh Dr K
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Thomae Gmbh Dr K filed Critical Thomae Gmbh Dr K
Publication of NO940524D0 publication Critical patent/NO940524D0/no
Publication of NO940524L publication Critical patent/NO940524L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Oppfinnelsen angår kondenserte 5-leddede heterocykler med den generelle formel A-B , (D hvor A, B, Yj og Y2 og Xx til X4 er som definert i krav l, deres tautomerer, deres stereoisomerer, innbefattet deres blandinger, og deres salter, spesielt deres fysiologisk akseptable salter, med uorganiske eller organiske syrer eller baser, som oppviser verdifulle farmakologiske egenskaper, fortrinnsvis aggregasjonshemmende virkninger, legemidler som inneholder disse forbindelser samt fremgangsmåter for deres fremstilling.
NO940524A 1993-02-16 1994-02-15 Kondenserte 5-leddete heterocykler, fremgangsmåte for deres fremstilling, og legemidler inneholdende disse forbindelser NO940524D0 (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4304650A DE4304650A1 (de) 1993-02-16 1993-02-16 Kondensierte 5-gliedrige Heterocyclen, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel

Publications (2)

Publication Number Publication Date
NO940524D0 NO940524D0 (no) 1994-02-15
NO940524L true NO940524L (no) 1994-08-17

Family

ID=6480585

Family Applications (1)

Application Number Title Priority Date Filing Date
NO940524A NO940524D0 (no) 1993-02-16 1994-02-15 Kondenserte 5-leddete heterocykler, fremgangsmåte for deres fremstilling, og legemidler inneholdende disse forbindelser

Country Status (10)

Country Link
EP (1) EP0611660A3 (no)
JP (1) JPH072839A (no)
AU (1) AU5513094A (no)
CA (1) CA2115737A1 (no)
DE (1) DE4304650A1 (no)
FI (1) FI940697A7 (no)
IL (1) IL108648A0 (no)
NO (1) NO940524D0 (no)
NZ (1) NZ250879A (no)
ZA (1) ZA941021B (no)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2751647B1 (fr) * 1996-07-25 1998-09-11 Synthelabo Derives de benzimidazole, leurs preparations et leurs applications en therapeutique
BR9812944A (pt) 1997-10-20 2000-08-08 Hoffmann La Roche Inibidores bicìclicos da cinase
PL364625A1 (en) 2001-02-23 2004-12-13 Merck & Co, Inc. N-substituted nonaryl-heterocyclic nmda/nr2b antagonists
JP2005509003A (ja) 2001-11-09 2005-04-07 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド タンパク質キナーゼインヒビターとして有用なベンゾイミダゾール化合物
AU2003257094A1 (en) 2002-08-08 2004-02-25 Boehringer Ingelheim Pharmaceuticals, Inc. Substituted benzimidazole compounds
CA2800237C (en) 2002-12-19 2016-05-17 The Scripps Research Institute Compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding
US7741341B2 (en) 2003-05-19 2010-06-22 Sanofi-Aventis Deutschland Gmbh Benzimidazole-derivatives as factor Xa inhibitors
EP1479676A1 (en) * 2003-05-19 2004-11-24 Aventis Pharma Deutschland GmbH Benzimidazole-derivatives as factor xa inhibitors
JP2007501189A (ja) 2003-08-01 2007-01-25 ジェネラブス テクノロジーズ，インコーポレイテッド フラビウイルス科に対する二環式イミダゾール誘導体
WO2005113523A1 (en) 2004-05-20 2005-12-01 Foldrx Pharmaceuticals, Inc. 2-((hetero) aryl)-benzoxazole compounds and derivatives, compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding
EP2222676A4 (en) * 2007-12-21 2011-10-26 Endacea Inc A1-adenosine receptor antagonistic
RU2586330C2 (ru) 2011-09-16 2016-06-10 Пфайзер Инк. Твердые формы ингибитора диссоциации транстиретина
WO2014125084A1 (en) 2013-02-14 2014-08-21 Technische Universität München Hydroxyindalpine derivatives and their medical use
WO2014151630A2 (en) 2013-03-15 2014-09-25 Irm Llc Compounds and compositions for the treatment of parasitic diseases
US9296754B2 (en) 2013-03-15 2016-03-29 Novartis Ag Compounds and compositions for the treatment of parasitic diseases
WO2014151729A1 (en) 2013-03-15 2014-09-25 Irm Llc Compounds and compositions for the treatment of parasitic diseases
CN107082782B (zh) * 2013-03-15 2020-03-20 海德拉生物科学有限责任公司 取代的黄嘌呤及其使用方法
BR112016014004B1 (pt) 2013-12-19 2022-11-01 Novartis Ag Compostos para tratamento de doenças parasíticas, seus usos, e composições farmacêuticas
US10112901B2 (en) 2014-07-03 2018-10-30 Shanghai Institute Of Pharmaceutical Industry Method for preparing dabigatran etexilate intermediate, and intermediate compound

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2208367B (en) 1987-07-09 1991-07-03 Alcatel Business Systems Franking machine
US5084466A (en) * 1989-01-31 1992-01-28 Hoffmann-La Roche Inc. Novel carboxamide pyridine compounds which have useful pharmaceutical utility
DE4124942A1 (de) * 1991-07-27 1993-01-28 Thomae Gmbh Dr K 5-gliedrige heterocyclen, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
DE4129603A1 (de) * 1991-09-06 1993-03-11 Thomae Gmbh Dr K Kondensierte 5-gliedrige heterocyclen, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
DE4214245A1 (de) * 1992-04-30 1993-11-04 Thomae Gmbh Dr K Tritiummarkierte fibrinogen-rezeptor-antagonisten, deren verwendung und verfahren zu ihrer herstellung
ATE140225T1 (de) * 1992-04-28 1996-07-15 Thomae Gmbh Dr K Tritiumarkierte fibrinogen-rezeptor-antagonisten, deren verwendung und verfahren zur ihrer herstellung

Also Published As

Publication number Publication date
DE4304650A1 (de) 1994-08-18
FI940697A7 (fi) 1994-08-17
FI940697A0 (fi) 1994-02-15
ZA941021B (en) 1995-08-15
AU5513094A (en) 1994-08-18
JPH072839A (ja) 1995-01-06
NZ250879A (en) 1995-09-26
EP0611660A2 (de) 1994-08-24
IL108648A0 (en) 1994-05-30
NO940524D0 (no) 1994-02-15
EP0611660A3 (de) 1994-09-14
CA2115737A1 (en) 1994-08-17

Similar Documents

Publication Publication Date Title
NO940524L (no)
NO922940L (no) Fem-leddete heterocykliske forbindelser, fremgangsmaate for deres fremstilling og legemidler inneholdende dem
NO923235L (no) Cykliske iminoderivater, samt fremgangsmaate for fremstilling av slike.
NO923466L (no) Heterocykliske forbindelser med 5 ledd, fremgangsmaate forfremstilling, samt legemidler som inneholder disse forbindelser
NO920957L (no) Cykliske urinstoffderivater og legemidler inneholdende disse forbindelser
NO933248L (no) Cykliske urinstoffderivater, legemidler inneholdende disse forbindelser, og fremgangsmåte for deres fremstilling
NO934501L (no) Karboksylsyrederivater, legemidler inneholdende disse forbindelser, og fremgangsmåte for deres fremstilling
NO940261L (no) 5-leddete heterocykler, fremgangsmåte ved fremstilling derav og legemidler som inneholder disse forbindelser
NO972881L (no) Piperazinderivater, legemidler som inneholder disse, anvendelse derav og fremgangsmåte for deres fremstilling
NO941677D0 (no) Tetrazolderivater av gallesyrer, fremgangsmåter for fremstilling og deres anvendelse som legemiddel
NO931526L (no) Cykliske iminoderivater, fremgangsmaate for deres fremstilling, og legemiddelpreparater inneholdende dem
CA2054850A1 (en) Cyclic imino derivatives, pharmaceutical compositions containing these compounds and processes for preparing them
NO941680D0 (no) Monomere gallesyrederivater, fremgangsmåte for fremstilling av dem og deres anvendelse som legemiddel
NO932120L (no) Bifenylderivater, legemidler inneholdende disse, og fremgangsmaate for deres fremstilling
RU95101048A (ru) Производные пролинамида, фармкомпозиция на их основе
NO984084L (no) 4-Amino-pyrimidin-derivater, medikamenter inneholdende disse forbindelser, deres anvendelse og fremgangsmÕte ved fremstilling derav
MX9803954A (es) Derivados de aminoacidos, composiciones farmaceuticas que contienen estos compuestos y procesos para prepararlos.
NO930517L (no) Benzimidazolylderivater, legemidler inneholdende disse, og fremgangsmaate for deres fremstilling
NO931527L (no) Cykliske iminoderivater, medisinpreparater inneholdende disse, og fremgangsmaate for deres fremstilling
NO924921L (no) Polyaspartamidderivater som adsorbsjonsmiddel for gallesyrer, polyaspartamidderivat lastet med gallesyrer og fremgangsmaater for fremstilling av disse, samt deres anvendelse som legemiddel
ES2140396T3 (es) Compuesto de tienodiazepina y su uso.
NO880473L (no) Fremgangsmaate til fremstilling av substituerte 3,4-dihydro-2h-benzopyraner og deres anvendelse som legemiddel.
KR890009389A (ko) 바이러스를 억제시키는 방법
NO301826B1 (no) Heterotricyklisk substituerte fenylcykloheksankarboksylsyrederivater, legemidler inneholdende dem og deres anvendelse for fremstilling av legemidler
NO883986D0 (no) Fremgangsmaate for fremstilling av n-(substituert alkyliden)-1,2,3,4-tetrahydro-9-akridinaminer og anvendelse derav som medikamenter.